论文部分内容阅读
晚期乳腺癌的治疗主要为姑息性治疗，对于激素受体阳性（HR+）/人类表皮生长因子受体2阴性（HER2-）并且没有内脏危机或威胁生命情况的晚期乳腺癌患者，内分泌治疗是主要的治疗方式。内分泌治疗的目标是延长生存期、改善或维持生活质量并尽可能地延迟化疗的启动。近年来，细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂被批准并应用于临床。CDK4/6抑制剂是新型靶向治疗药物，其主要应用于HR+/HER2-乳腺癌患者，使相关内分泌治疗模式有了突破性的进展。目前，被美国食品药品监督管理局批准的CDK4/6抑制剂主要有Palbociclib、Ribociclib和Abemaciclib。与传统的单纯内分泌治疗相比，CDK4/6抑制剂联合内分泌治疗显著延长了乳腺癌患者的无进展生存期，且耐受性良好。主要介绍CDK4/6抑制剂联合内分泌治疗在HR+/HER2-乳腺癌治疗中的临床研究进展，比较不同CDK4/6抑制剂在临床应用中的不良反应。“,”The treatment of advanced breast cancer is mainly palliative treatment. Endocrine therapy is the main treatment for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients without visceral crisis or life-threatening conditions. The goal of endocrine therapy is to prolong survival, improve or maintain quality of life, and delay the start of chemotherapy as much as possible. In recent years, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have been approved and used clinically. CDK4/6 inhibitors are a new type of targeted therapy drugs, which are mainly used in HR+/HER2- breast cancer patients, making a breakthrough in related endocrine therapy models. Currently, the CDK4/6 inhibitors approved by the US Food and Drug Administration are Palbociclib, Ribociclib and Abemaciclib. Compared with traditional endocrine therapy alone, CDK4/6 inhibitor combined with endocrine therapy significantly prolongs the progression-free survival of breast cancer patients, and is well tolerated. In this paper, the clinical research progress in CDK4/6 inhibitor combined with endocrine therapy for HR+/HER2- breast cancer was introduced, and the adverse reactions of three CDK4/6 inhibitors mentioned above in clinical application were analyzed.